Novacyt announced recently that its molecular testing division, Primerdesign, has inked an exclusive supply agreement with Genesis Diagnostics.

Primerdesign will develop and supply 384-well plate molecular assay panels in the areas of respiratory, women's health, sexually transmitted, wound, and urinary tract infections to Genesis to use in its Langhorne, Pennsylvania-based clinical service laboratory.

The deal, which is expected to begin in early 2019, is set to last for at least five years and is valued at a minimum of $3 million, Novacyt said. Genesis will buy a minimum of $600,000 worth of products each year.

"The agreement builds on our broad product offering and the increasing geographic reach of our molecular diagnostics business," Novacyt CEO Graham Mullis said in a statement. "It also highlights Primerdesign's pivotal role in assay development as we continue to grow our relationships with leading diagnostic companies, further increasing our reputation as a leading clinical assay development and supplies partner. The minimum revenues expected from this partnership further support our investment in our B2B partnerships strategy and we expect Genesis Diagnostics to order significantly more than the contracted minima."

Today's deal follows an agreement announced in September between Novacyt and Applied Microarrays to develop microarray-based SNP assays for diagnostic applications.